-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Of all leukemias , chronic lymphocytic leukemia (CLL) is the most prevalent type in the global population
Of all leukemias , chronic lymphocytic leukemia (CLL) is the most prevalent type in the global population
Determination of the Bax/Bcl-2 ratio may be a good predictive tool for identifying the prognosis and prognosis of patients with chronic lymphocytic leukemia (CLL) to determine the timing and type of treatment, therefore, a prospective study of 100 newly diagnosed CLL patients was performed.
Figure 1: CD49d, Bax and Bcl-2 detected by flow cytometry in 2 CLL patients
Figure 1: CD49d, Bax and Bcl-2 detected by flow cytometry in 2 CLL patients
The expression of Bax and Bcl-2 in peripheral blood was measured by flow cytometry
Figure 2: Prediction of overall survival based on the ROC curve of the Bax/Bcl-2 ratio
Figure 2: Prediction of overall survival based on the ROC curve of the Bax/Bcl-2 ratio
Figure 3: Kaplan-Meier survival analysis using Bax/Bcl-2 ratio for A, overall survival (OS) and B, progression free survival (PFS)
Figure 3: Kaplan-Meier survival analysis using Bax/Bcl-2 ratio for A, overall survival (OS) and B, progression free survival (PFS)
By receiver operating characteristic (ROC) curve detection, the best Bax/Bcl-2 ratio for predicting survival was 1.
The researchers concluded that a lower Bax/Bcl-2 ratio was associated with poorer prognosis, as evidenced by lower OS and PFS in CLL patients
Original source:
Original source:Helaly NA, Esheba NE, Ammo DEA, Elwan NM, Elkholy RA.
Helaly NA, Esheba NE, Ammo DEA, Elwan NM, Elkholy RA.
High Bax/Bcl-2 ratio is associated with good prognosis and better survival in patients with B cell chronic lymphocytic leukemia.
Leuk Res.
2021 Aug;107:106604.
doi : 10.
1016/j.
leukres.
2021.
106604.
Epub 2021 Apr 30.
PMID: 33965850.
Helaly NA, Esheba NE, Ammo DEA, Elwan NM, Elkholy RA.
High Bax/Bcl-2 ratio is associated with good prognosis and better survival in patients with B cell chronic lymphocytic leukemia.
Leuk Res.
2021 Aug;107:106604.
doi: 10.
1016/j.
leukres.
2021.
106604.
Epub 2021 Apr 30.
PMID: 33965850.
Leave a comment here
